An isoform of PSA the percentage of which is lower in patients with prostate cancer than in those with benign prostatic hypertrophy.
In patients with clinically localized prostate cancer the free/total PSA ratio does not predict for the final pathological tumor stage or grade and adds nothing to the PSA and Gleason score.